Skip to content

Rosiglitazone

Peroxisome Proliferator Receptor gamma Agonist — ALIMENTARY TRACT AND METABOLISM

Also known as: rosiglitazone HCl, rosiglitazone hydrochloride, rosiglitazone maleate, rosiglizole

OfmFDA approvedATC A10BD03ATC A10BD04ATC A10BG02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Rosiglitazone is an ofm drug in the Peroxisome Proliferator Receptor gamma Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1999. Its mechanism of action is classified as Peroxisome Proliferator-activated Receptor gamma Agonists. DrugCentral lists 23 molecular targets, including Agtr1, Pparg and CISD1. Recorded indications include Treatment Refractory Type 2 Diabetes Mellitus.

  • Approval status: ofm (first approved 1999 by the FDA).
  • Drug class: Peroxisome Proliferator Receptor gamma Agonist; Thiazolidinedione.
  • Mechanism of action: Peroxisome Proliferator-activated Receptor gamma Agonists.
  • Molecular targets: Agtr1, Pparg, CISD1 and PPARA (23 listed in DrugCentral).
  • Indications: Treatment Refractory Type 2 Diabetes Mellitus.
  • ATC code: A10BD03 (Combinations of oral blood glucose lowering drugs).
  • Molecular formula: C18H19N3O3S; molecular weight 357.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Treatment Refractory Type 2 Diabetes Mellitus

Contraindications (47)

  • Acute vomiting
  • Adrenal cortical hypofunction
  • Alcohol intoxication
  • Alcoholism
  • Angina pectoris
  • Asthenia
  • Autonomic dysreflexia
  • Body fluid retention
  • Breastfeeding (mother)
  • Cardiogenic shock
  • Cerebrovascular accident
  • Chronic heart failure
  • Cobalamin deficiency
  • Decompensated cardiac failure
  • Dehydration
  • Disease of liver
  • Disorder of coronary artery
  • Drug-induced hepatitis
  • Fever
  • Fever greater than 100.4 Fahrenheit
  • Fracture of bone
  • Glucose-6-phosphate dehydrogenase deficiency anemia
  • Hemolytic anemia
  • Hepatic porphyria
  • Hypoglycemic disorder
  • Hypopituitarism
  • Infectious disease
  • Ketoacidosis
  • Kidney disease
  • Lactic acidosis
  • + 17 more

Mechanism & targets

Mechanism of action (MoA)Peroxisome Proliferator-activated Receptor gamma Agonists
Established pharmacologic classPeroxisome Proliferator Receptor gamma Agonist; Thiazolidinedione

Molecular targets (23)

TargetGeneActionActivity
Type-1A angiotensin II receptorAgtr1unknownKi 9.64
Peroxisome proliferator-activated receptor gammaPpargunknownEC50 7.52
CDGSH iron-sulfur domain-containing protein 1CISD1unknownKi 7.51
Peroxisome proliferator-activated receptor alphaPPARAunknownEC50 7.41
Peroxisome proliferator-activated receptor alphaPparaunknownIC50 7.10
Peroxisome proliferator-activated receptor gammaPPARGagonistEC50 7.04
CDGSH iron-sulfur domain-containing protein 1Cisd1unknownIC50 5.96
CDGSH iron-sulfur domain-containing protein 2CISD2unknownIC50 5.64
Free fatty acid receptor 1FFAR1agonistEC50 5.60
Thromboxane-A synthaseTBXAS1unknownIC50 5.45
Peroxisome proliferator-activated receptor deltaPPARDunknownEC50 5.44
Carbonic anhydrase 2CA2unknownIC50 5.39
Amine oxidase [flavin-containing] BMAOBunknownKi 5.38
Sodium/bile acid cotransporterSLC10A1unknownIC50 5.29
Amine oxidase [flavin-containing] BMaobunknownKi 5.24
Bile salt export pumpABCB11unknownIC50 5.19
Retinoic acid receptor gammaRARGunknownKi 5.00
Retinoic acid receptor RXR-alphaRXRAunknownKd 4.82
Amine oxidase [flavin-containing] AMAOAunknownKi 4.56
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 4.53

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1999-05-25FDA—SB PHARMCO

ATC classification

ATC codeTherapeutic hierarchy
A10BD03ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BD04ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BG02ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Thiazolidinediones

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Myocardial infarction38201.9
Cardiac failure congestive36409.3
Coronary artery disease18190.0
Cerebrovascular accident12664.6
Acute myocardial infarction7613.7
Coronary arterial stent insertion5255.8
Coronary artery bypass4849.5
Angina unstable2658.0
Myocardial ischaemia2057.9
Vascular graft1504.1
Ischaemic cardiomyopathy1206.0
Angina pectoris1178.4

Chemical structure

Molecular formulaC18H19N3O3S
Molecular weight357.43 g/mol
CAS number122320-73-4
InChIKeyYASAKCUCGLMORW-UHFFFAOYSA-N
PubChem CID77999
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rosiglitazone used for?

DrugCentral lists the following indications for Rosiglitazone: Treatment Refractory Type 2 Diabetes Mellitus.

How does Rosiglitazone work?

Rosiglitazone is classified as Peroxisome Proliferator-activated Receptor gamma Agonists; its molecular targets in DrugCentral include Agtr1, Pparg, CISD1 and PPARA.

When was Rosiglitazone first approved?

Rosiglitazone was first approved by the FDA in 1999.

What drug class does Rosiglitazone belong to?

Rosiglitazone is in the Peroxisome Proliferator Receptor gamma Agonist class.

What is the chemical formula of Rosiglitazone?

Rosiglitazone has the molecular formula C18H19N3O3S and a molecular weight of 357.43 g/mol.

Browse: all drugs starting with R · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1999-05-25
AgencyFDA
Targets23
Indications1
FormulaC18H19N3O3S
DrugCentral ID2405
Interactive profile